NCT04378842 (COVID-BMR) is a clinical trial in Sars-CoV2, sponsored by University Hospital, Lille.

Who is sponsoring NCT04378842?

NCT04378842 is sponsored by University Hospital, Lille.

What condition does NCT04378842 study?

NCT04378842 studies Sars-CoV2, Critical Illness.

Is NCT04378842 still recruiting?

NCT04378842 is currently completed. Last updated 5 October 2022.

Last reviewed 2022-10-05 · How we verify

NCT04378842: COVID-BMR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 and ICU-acquired MDR Bacteria

Completed Last updated 5 October 2022

What this trial tests

trial in Sars-CoV2 in 368 participants. Completed in 26 July 2021.

Timeline

18 May 2020

Primary endpoint
26 July 2021

26 July 2021

Quick facts

Lead sponsor	University Hospital, Lille
Status	Completed
Study type	OBSERVATIONAL
Enrollment	368
Start date	18 May 2020
Primary completion	26 July 2021
Estimated completion	26 July 2021
Sites	7 locations across France

Conditions studied

Sars-CoV2 — all drugs for Sars-CoV2 →
Critical Illness — all drugs for Critical Illness →

Sponsor

University Hospital, Lille

Who can join

18 and older, any sex, with Sars-CoV2 or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sars-CoV2

Currently open trials in the same condition.

NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting

Other University Hospital, Lille trials

Trials by the same sponsor.

NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04378842 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
Last refreshed: 5 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04378842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing